Nordic AML Group

Webinar - Ask the expert: FLT3 MRD testing in AML patients
2026-03-17 17:00 - 18:00 (Europe/Paris)
Take the chance to join an Astellas Pharma sponsored webinar with Dr. Mark J. Levis, MD, PhD, Baltimore, USA, entitled Ask the expert: FLT3 MRD testing in AML patients via Teams with the following agenda:
Assess the current minimal residual disease testing modalities/methods
 Evaluate appropriate timing and efficacy of different FLT3 MRD testing modalities
 Summarize the appropriate treatment strategies in a post-transplant setting
 Best practice sharing in developing/setting up FLT3 MRD testing
More info and register here.

Germline Predisposition to Myeloid Neoplasms - Case discussions
2026-03-05 15:00 - 16:00 (Europe/Paris)
Join the MDR for patients with germline predisposition for hematological malignancies.
This meeting is for clinicians within the Nordics via this Zoom-link.
If you want to discuss a case, please send 1-2 summary slides with the most important information to Panagiotis Baliakas (panagiotis.baliakas@igp.uu.se), Uppsala, Sweden.

NAMLG – Steering group meeting
2026-03-03 16:00 - 17:00 (Europe/Paris)
Agenda and meeting link will be sent via e-mail.

Webinar - Innovations in AML care: Integrating Novel Treatments into Nordic Practice
2026-02-26 14:00 - 15:15 (Europe/Paris) | https://www.namlg.org/event/webinar-innovations-in-aml-care/
The Nordic AML Group’s Educational Working Group invites you to a scientific webinar focusing on recent innovations in the treatment of AML and their implementation in Nordic clinical practice.
The webinar will feature three expert speakers covering:
– The evolving AML treatment landscape by professor Gail Roboz (New York)
– Early Nordic experience with new AML therapies and ongoing Nordic studies by professor Bjørn Tore Gjertsen (Bergen)
– Access pathways and future developments in AML care by associate professor Anne Louise Tølbøll Sørensen (Copenhagen)
Aim: To provide a clinically relevant and up-to-date overview of emerging therapeutic approaches for AML, with particular emphasis on feasibility, relevance, and early adoption within the Nordic region.
Format: Webinar via Zoom via this link
Sponsorship: Sponsored by Otsuka. The sponsor has no influence on the scientific content or agenda.
#################################
Agenda – 2026-02-26 – 14:00 – 15:15 (CET)
14:00 – 14:05 – Welcome & Introduction
14:05 – 14:20 – The Evolving AML Landscape, Professor Gail Roboz (New York)
14:20 – 14:35 – From Data to Practice: Early Nordic Experience with New AML Treatments, Professor Bjørn Tore Gjertsen (Bergen)
14:35 – 14:45 – Discussion
14:45 – 15:00 – Ongoing Nordic Studies, Access Pathways, and What’s Coming Next, Associate professor Anne Louise Tølbøll Sørensen (Copenhagen)
15:00 – 15:10 – Discussion
15:10 – 15:15 – Closing remarks
#################################

Best of ASH 2025 by Lund
2026-01-20 15:00 - 19:00 (Europe/Paris)
At Best of ASH 2025, hematologists in Lund, Sweden present their top picks from the annual meeting of the American Society of Hematology (ASH) cutting through the volume to focus on data that change how we treat patients. Expect concise, expert-led updates on key trials, late-breaking abstracts, and their real-world implications across hematology.
Live on YouTube: https://www.youtube.com/live/DJrW-8hEHvI

NAMLG - Steering group meeting
2026-01-13 16:00 - 17:00 (Europe/Paris)

Personalized Medicine in the Treatment of AML
2025-12-17 15:00 - 17:00 (Europe/Paris)
Jazz Pharmaceuticals is pleased to invite hematologists from the Nordic AML Group to join a distinguished academic webinar featuring Prof. Dr. med. Lars Bullinger and Prof. Bjørn Tore Gjertsen, two leading experts in hematology and leukemia research.
Find more info using this link.
Register using this QR code

Nordic AML Meeting 11-12 September 2025
2025-09-11 - 2025-09-12
Save the dates for the upcoming Nordic AML Meeting in Bergen, Norway, 2025.

Presentation of a Nordic platform for future collaborative projects on TP53 mutated myeloid malignancies
2025-09-10 20:00 - 21:30 (Europe/Paris)
It’s an open meeting for clinicians and preclinical researchers but meant for those that are actually interested to take part in future Nordic collaborative TP53 related myeloid research.
The meeting will be held at Hotel Norge, Bergen, in connection with the NAMLG meeting, Room number will be announced at the hotel reception.
The meeting will also be possible to attend by Zoom.
Chair: Professor Sören Lehmann, Sweden

AML Course Day 10 September 2025
2025-09-10
The Educational Working Group is planning an “AML Course Day” in conjunction with the Nordic AML Meeting in Bergen 2025.
The AML Course Day covers topics such as the current diagnostics and therapeutics, the latest with regard to MRD as well as clinically inclined discussions on emergencies and infectious problems in AML.
The AML Course Day will be open for registration for physicians in the Nordics who take care of patients with AML.
More information is coming, but save-the-date!

The 13th CCBIO Annual Symposium
2025-05-13 - 2025-05-14
CCBIO has the pleasure of inviting you to the 13th CCBIO Annual Symposium May 13-14, and now, PREFINAL PROGRAM is available.
To participate, please register within April 1.
There will be a strong scientific program including a range of international speakers, among them Sir David Lane, Eva Hellström-Lindberg, Theodoros Foukakis, Anna Dimberg, Steinar Ø. Thoresen, Gema Moreno-Bueno and Jean Albrengues.

The c-myc Single Cell Satellite Seminar
2025-05-12
The newly established Jebsen Centre for Myeloid Blood Cancer (c-myc) will have their first Annual c-myc Seminar as a full-day satellite to CCBIO’s 13th Annual Symposium and will showcase recent advancements in single-cell genomics, transcriptomics, proteomics, and preclinical trials, setting the stage for future clinical applications. The event will bring together leading researchers to explore how single-cell resolution can advance cancer treatment and improve patient outcomes. For program, registration and practical information, please consult the seminar website.

NAMLG Lunch Meeting in Munich
2025-03-17 12:00 - 14:00 (Europe/Paris)
For Nordic AML physicians attending the Acute Leukemia Symposium ISALXIX in Munich 16-19th March 2025, You are cordially invited to a NAMLG Lunch Meeting in
on Monday March 17th, 12.00-14.00. Find more info in this flyer. [With support from Servier and the organizing committee in Munich.]

NAMLG Breakfast Meeting @ ASH
2024-12-07 07:00 - 09:00 (America/Los_Angeles) | 675 L St, San Diego, CA 92101, USA, 675 L Street, San Diego, CA, 92101, United States
You are cordially invited to the NAMLG Breakfast Meeting, held during ASH in San Diego.
Date: Saturday, December 7th
Time: 7:00 AM – 9:00 AM
This event is generously sponsored by AbbVie.
To register, please contact Bjørn Tore Gjertsen (Bjorn.Gjertsen@uib.no).

MNSCT 2024 Meeting
2024-11-21 12:00 - 17:00 (Europe/Paris)
MNSCT 2024 Meeting
Date: 21 November 2024
Venue: Grand Hotel, Lund, Sweden or online
Registration: https://mkon.nu/mnsct_2024/registration
Program
12:00-12:55 Lunch, registration starts at 11.45
13:00-13:05 Welcome/Introduction (Assoc. Prof. Andreas Björklund, Stockholm, Assoc. Prof. Jörg Cammenga, Lund)
Session 1:
13:05-13:45 Prof. Dr. Thomas Schröder, University Hospital Essen, Essen Germany — “Pharmacological preemptive and prophylactic approaches to prevent/treat relapse of myeloid neoplasms after allo SCT”
13:40-14:20 Assoc. Professor Dr. Luca Vago, Milan, Italy — “Mechanisms of immune escape after allogeneic stem cell transplantation”
14:20-14:30 Coffee break
Session 2:
14:30-15:10 Ass. Professor Dr. A, Mishra, MD (Tampa, Florida) — “Targeted agents post- allo HSCT based on mutational status”
15:15-15:55 Ass. Professor Dr. Jacqueline S. Garcia, MD (Harvard Medical School, Dana-Farber Cancer Institute) — “Post transplant maintenance: Finding the sweet spot”
16:00-16:55 Plenary discussion (all speakers (virtual/local) + moderators)
16:55-17:00 Closing remarks

mIDH1-mutated AML: ivosidenib in clinical practice
2024-11-21 00:00 - 13:00 (Europe/Paris)
This Servier arranged webinar is for hematologists. The agenda for the webinar is:
12:00-12:05 – Introduction by Erik Holgén, Product Manager, Servier
12:05-12:30 – Prof. Dr. Michael Heuser – Will present the AGILE study and the clinical implications of the study results.
12:30-12:45 – Docent Vladimir Lazarevic – Focusing on treatment of mIDH1 AML patients in the future
12:45-13:00 – Questions & Answers
——————-
Unable to attend at this time? Register anyway to receive the recording afterwards.
Click here to register

Evolving treatment options for patients with AML ineligible for intensive chemotherapy
2024-10-29 16:00 - 18:00 (Europe/Paris)
Find more info in this flyer.
Location: Aarhus University Hospital AUH SYD, auditorium C114-101. Indgang C, C110 or join online.

Please send your registration for the meeting before October 16th to Daniel Tuyet Kristensen (dankrt@rm.dk). Please note if you will participate in person or online to receive a link.

Webinar - Azacitidine-Venetoclax: latest clinical updates
2024-09-24 15:00 - 16:30 (Europe/Paris)
The NAMLG’s Educational Working Group is hosting a webinar on September 24, 2024, from 15:00 to 16:30 CEST. The webinar will provide the latest insights on using Aza-Ven in AML treatment including discussions from a Nordic perspective. Topics will include its application as a first-line treatment, dosing optimizations, and strategies for maintenance therapy.
You can find the program here.
There is no registration required as the webinar will be sent via Zoom, see the program for details and passcode.
The webinar is supported by AbbVie and the KG Jebsen Centre for Myeloid Blood Cancer at the University of Bergen.

Workshop & Talks: Nanopore Sequencing Technologies
2024-09-13 09:30 - 15:30 (Europe/Paris)
Find more information via this link.

Join the workshop online, by using this Zoom link:
https://nanoporetech.zoom.us/j/88211217159?pwd=[REDACTED]
Passcode: [REDACTED]

or join in place at this location:

Auditorium 2 & 4, BB-Bygget. Haukeland Universitetssykehus – Jonas Lies vei 91. 5009 Bergen

Opening Symposium of the KG Jebsen Centre for Myeloid Blood Cancer, C-MYC, in Bergen
2024-09-11 - 2024-09-12
Join the opening symposium of the new KG Jebsen Centre for Myeloid Blood Cancer, C-MYC, on September 11 and 12, 2024 in Bergen!
Find the program and register using this link.

EHA Meeting: Nordic Lunch meeting
2024-06-15 11:30 - 13:30 (Europe/Paris)
NAMLG lunch meeting to be held in Sponsor Meeting Hub (in Hall 9) between 11:30 and 13:30 on Saturday 15th June.
Preliminary agenda

11:30-11:35: Welcome, v. Bjørn-Tore Gjertsen, Chairman
11:35-11:45 Remarks from the sponsor v. Delbert Pharma
11:45-12:25: NAMLG activities:

11:45-11:55: Scientific working group, Sören Lehmann
11:55-12:05: Educational working group, Albin Österroos/Daniel Tuyet Kristensen
12:05-12:25: Trial working group, Bjørn Tore Gjertsen

Drug repurposing trials in RR AML: Melphalan for hypoplastic AML / DDX41 mutated (Jakob Dalgaard)
HUVAMER and Early response evaluation (Bjørn Tore Gjertsen)

12:25-12:55: Diagnostic working group, Linda Fogelstrand
12:55-13:05: About the 2025 biannual NAMLG meeting, Björn Tore Gjertsen
13:05-13:10: Steering group meeting schedule for 2024/2025, Daniel Tuyet Kristensen
13:10-13:30: Any other business and mingle with colleagues

For the Teams link, please contact Daniel (dakr@dcm.aau.dk) or Albin (albin.osterroos@medsci.uu.se).
Please, find more info at Invitation letter – NAMLG lunch – Madrid 2024.

NAMLG Educational Working Group meeting
2024-05-08 15:00 - 16:00 (Europe/Paris)
Join via Teams using this link.

Nordic MPAL meeting
2024-05-06 15:30 - 16:30 (Europe/Paris)
For more information, please contact Vladimir Lazarevic, Lund, Sweden.
Join via Teams using this link.

CCBIO Seminar – Mika Kontro - Functional Screening for Precision Medicine Approaches in AML
2024-03-21 14:30 - 15:30 (Europe/Paris)
Dr. Mika Kontro will discuss the methods for personalizing AML therapies using functional screening. He will provide an overview of the current data implementation and share insights from ongoing prospective trials employing functional screening. Furthermore, Dr. Kontro will focus on the VenEx trial, which utilizes ex vivo drug sensitivity testing to identify AML patients who can benefit from the azacitidine-venetoclax regimen.
More info can be found on this link.
Join via Zoom using this link.
No registration necessary.

Nordic AML 'poster walk' post-ASH
2024-03-12 15:00 - 17:00 (Europe/Paris)
Nordic AML posters at ASH 2023 – Webinar – 2024-03-12 – 15:00-16:20 (CET)
Join us for a webinar where we delve into the intricacies of showcased Nordic AML posters at the latest ASH Annual Meeting in December 2023. Here we aim for an opportunity to gain valuable insights, connect with peers, and stay at the forefront of AML innovation.

Join via Zoom: https://uu-se.zoom.us/j/63956689621

Tentative agenda (updated 2024-03-04)
15:00 – 15:05 – Welcome
15:05 – 15:15 – Elory Leonard, Stockholm, Sweden
Protective Function of Human Skin Mesenchymal Niches for Acute Myeloid Leukemia-Initiating Stem Cells
15:15 – 15:25 – Ida Vänttinen, Helsinki, Finland
Targeting Venetoclax Resistance in TP53-Mutated Acute Myeloid Leukemia
15:25 – 15:35 – Claudia Schöllkopf, Copenhagen, Denmark
Dose Escalation of HLA-A2-WT1 CD3 T-Cell Bispecific Antibody in a Phase I Study in Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML)
15:35 – 15:45 – Sofie Johansson Alm, Gothenburg, Sweden
Deep Sequencing Is a Widely Applicable Tool for Relapse Prediction in Acute Myeloid Leukemia with Mutated NPM1
15:45 – 15:55 – Øystein Sefland, Bergen, Norway
Intradermal Vaccination with Vididencel in MRD+ AML-Patients Leads to Increase in Antigen Presenting Cells and T-Cells to the Injection Site, Visualized Using Imaging Mass Cytometry, Showing Local Immune Cell Interactions Leading to Systemic Immune Responses
15:55 – 16:05 – Hanna Duàn, Helsinki, Finland
Primary Acute Myeloid Leukemia Cells Trigger Distinct Activation Patterns in Expanded NK Cells
16:05 – 16:15 – Somadri Ghosh, Lund, Sweden
H2-K1 on MLL-AF9 Leukemia Cells Facilitates the Escape of NK Cell-Mediated Immune Surveillance
16:15 – 16:25 – Jonas Bouhlal, Helsinki, Finland
High-Throughput Screens Identify NEDD8 Inhibition As a Strategy to Augment Natural Killer Cell Cytotoxicity Against Blood Cancers
16:25 – 16:30 – Closing remarks

Arranged by the NAMLG Educational Working Group (namlgewg@gmail.com)

Early Response Evaluation by Single-Cell Signaling Profiling in AML
2024-01-25 16:00 - 17:00 (Europe/Paris)
Webinar to be held January 25 at 16:00
This is in Standard Biotools’ (former Fluidigm) Scientist in the Spotlight series.
More info and registration on this link.
Hear about:
Insights into AML response: Discover the initial signaling response to standard induction chemotherapy in a cohort of 32 AML patients.

Predicting 5-year survival: Learn about the significant predictors of patient 5-year overall survival in this cohort, specifically the reduction of extracellular-signal-regulated kinase (ERK) 1/2 and p38 mitogen-activated protein kinase (MAPK) phosphorylation.

Importance of signaling pathways: See how RNA sequencing and proteomics confirm the mass cytometry data and highlight the potential for this assay to be used in the future of precision oncology.

NAMLG TWG Meeting - I - 24-01-2024 15:30-16:30 CET
2024-01-24 15:30 - 16:30 (Europe/Paris)
Link and passcode for Teams meeting sent separately.
Agenda:

Update on potential LD-VenEx amendment trial comparing poDEC/LD-VenEx vs. AZA/LD-VenEx (5 min + 10 min discussion).
NAMLG – platform trial structure concept (5 min): Infrastructure with standing collaboration contracts (clinical trial agreement – CTA) and data processing agreements (DPAs) applicable for all types of trials. This would allow to open trials at one Nordic sponsor site and recruit pts from all Nordic Sites without the requirement to establish new CTAs / DPAs for each trial with individually. Ultimately, this will establish the NAMLG as partner for pharma-sponsored trials as well as to obtain funding for IIT.
List/overview of ongoing, already planned, and potential future AML trials in the Nordics.
Presentation and discussion of ongoing and potential novel AML trials

Martin Jädersten – Salvage Treatment + HU (5 min + 5 min discission
Oxcia: Presentation of MAATEO Karonudib + Dauno for RR AML (7 min+ 3 min discussion)
Trials suggested in previous mail by Bjørn Tore Gjertsen (6 min + 4 min discussion)

Webinar - Immunotherapy: a new perspective for AML maintenance treatment?
2023-12-06 15:30 - 16:30 (Europe/Paris)
Agenda
[Post updated 2024-03-16]
Download a recorded version of the webinar using this link.
Find the HCP guide for Ceplene on this link.
Ceplene can be ordered with the Nordic item number (Vnr.) 46 54 33, through:
Oriola in Sweden
TMJ in Denmark
Your local wholesaler, Apotek 1, NMD and Alliance in Norway
———————————————
AML patients not candidates to allotransplant: relapse risk and therapeutics (Pr Bjorn Gjertsen)
Immunotherapy with Histamine dihydrochloride in association with low-dose interleukin-2 (HDC/IL-2) for relapse prevention (Pr Kristoffer Hellstrand)
Conceivable indications of HDC/IL-2 for post-remission in AML? (Pr Bjorn Gjertsen, Dr Martin Jädersten, Dr Lovisa Wennström)
For more info, click here.
For registration, click here.

Myeloid Neoplasia StemCellTransplant (MNSCT) Nordic workshop
2023-11-30 12:00 - 21:00 (Europe/Paris)
We are thrilled to invite you all to the first MNSCT workshop. The program is planned by a scientific committee from the Swedish-Norwegian BMT-group and the Swedish AML-group. The overarching aim of this meeting is to stimulate discussions around topics within the Nordic community.
Please register for this event using this link (deadline 2023-10-27).
Click here for more information and the program.
The workshop is supported by medac Nordics.

Nordic AML webinar
2023-11-08 08:00 - 17:00 (Europe/Paris)
Thank you to all participants for taking part in the Nordic AML webinar 2023-11-08. For a recording of the webinar use this link.
